Solute carrier family 25 member 19 (SLC25A19) is a transporter protein of thiamine pyrophosphate across cellular membranes, which is needed as a cofactor for multiple metabolic enzymes and is important for homeostasis regulation. It was hypothesized that SLC25A19 may be a pan-cancer marker and a therapeutic target, and more concretely in hepatocellular carcinoma (HCC).
The U.S. FDA granted breakthrough device designation to Mursla Bio Ltd.'s Evoliver. The biopsy blood test uses extracellular vesicles to survey hepatocellular carcinoma in high-risk cirrhotic patients.
Sunshine Biopharma Inc. has completed additional studies on orthotopic human tumor models in mice confirming its K1.1 mRNA lipid nanoparticle (K1.1-mRNA-LNP) product as a novel therapeutic agent for human hepatocellular carcinoma (HCC).
Bispecific antibodies have gotten plenty of press in recent years, but less prominent in headlines are bifunctional ones – i.e., those that boast one binding site for an antigen and another site for a non-antibody molecule such as a toxin or drug, taking aim at a single target and bringing a secondary function for extra oomph.
Hepatocellular carcinoma (HCC) represents about 90% of all cases of liver cancer and has a poor prognosis, with a 5-year survival rate of about 18%. Previous findings had shown that RNA 5-methylcytosine (m5C) plays an important role in HCC progression, where the impairment of ferroptosis plays a crucial role in HCC progression.
Metabolic reprogramming in cancer involves glycolytic enzymes acquiring noncanonical functions and acting as protein kinases, which contribute to tumor progression and present new therapeutic opportunities. While hexokinase domain-containing protein 1 (HKDC1), a hexokinase family member, has been implicated in tumor growth and immune evasion, its nonmetabolic roles remain poorly understood.
Human antigen R (HuR) controls the stability and translation of several transcripts that are key for metabolism, inflammation and cancer, including TNF-α or MYC. Previous findings have shown the pro-tumorigenic role of HuR in hepatocellular carcinoma (HCC), and its inhibition to be involved in metabolic dysfunction-associated steatohepatitis (MASH).
Researchers from Universitatsklinikum Heidelberg presented data from a study that investigated the role of strawberry notch homolog 1 (SBNO1) in the development of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA).
Researchers from Medizinische Hochschule Hannover and affiliated organizations reported data from studies aimed to identify non-coding microRNAs (miRNAs) with therapeutic potential against liver fibrosis in hepatocellular carcinoma (HCC). Functional screening of patient-derived primary human hepatic myofibroblasts, followed by in vivo validation in mouse models of fibrosis, were performed in search of antifibrotic miRNAs.
